OHI

Analyst Note: Omega Healthcare Investors, Inc. (OHI)

Date: 2026-06-13 Current Price: $44.53

1. Structural Readiness

• State: Context-only
• Conservative Entry: —
• Breakout Level: —
• Extension: —
• ATR Current: 2.4% (Sub-threshold volatility)

2. Thesis Layer

This is a TACTICAL, setup-led name with NO named secular thesis at this date. There is no macro or thematic thesis (e.g., "Silver Tsunami" or "Regulatory Tailwind") explicitly attached to this specific setup in the current evidence base. The conviction must be derived strictly from the quality of the business fundamentals, the strength of the capital deployment strategy, and the structural readiness of the setup once defined. We are judging this name on its operational execution and balance sheet strength rather than a pre-existing macro narrative.

3. Business Overview

Omega Healthcare Investors, Inc. operates as a Real Estate Investment Trust (REIT) focused on financing and capital provision to the long-term healthcare industry.

• Core Business Model: The company primarily utilizes a triple-net lease framework to provide financing to healthcare operators. It also employs RIDEA (REIT Investment Diversification and Empowerment Act) structures to own and operate facilities through third-party managers.
• Portfolio Composition: As of March 31, 2026, the portfolio comprised 1,039 operating healthcare facilities. This includes:
• 553 Skilled Nursing Facilities (SNFs)
• 340 Assisted Living Facilities (ALFs)
• 19 Independent Living Facilities (ILFs)
• 16 Specialty Facilities
• 1 Continuing Care Retirement Community (CCRC)
• Geographic Reach: Operations span the United States and the United Kingdom, with recent expansion into Canada via a real estate loan commitment.
• Capital Deployment & Activity:
• Q1 2026 Activity: The company completed $251 million in new investments (excluding $13 million in CapEx) and $326 million year-to-date.
• Asset Recycling: In Q1 2026, the company reclassified 18 facilities in Maryland and West Virginia ($225.1 million net book value) to assets held for sale. Notably, on April 1, 2026, 12 CommuniCare facilities were sold for $326.3 million, realizing a significant premium over book value.
• Strategic Acquisitions: On January 1, 2026, Omega acquired a 9.9% equity interest in Saber Healthcare Holdings, LLC for $92.8 million.
• Lease Quality: As of December 31, 2025, approximately 86.0% of triple-net operating leases have terms expiring after 2030. The average annualized yield from these leases was approximately 10.4%.
• RIDEA Platform: Management has begun utilizing RIDEA structures to own and operate ALFs and ILFs, aiming to capture operational upside. Management expects the redeployment of capital into these structures to result in approximately $0.03 of annual AFFO and FAD accretion.

4. Archetype and Conviction

• Archetype: Quality Compounder
• Rationale: The company demonstrates a disciplined approach to capital allocation, evidenced by the successful sale of assets at a premium (CommuniCare sale) and the strategic acquisition of equity in Saber Healthcare. The high lease duration (86% > 2030) and strong yield (10.4%) suggest a stable, income-generating core. The shift toward RIDEA structures indicates a strategic evolution to capture operational alpha, a hallmark of a compounder seeking to enhance per-share value over time.
• Valuation Context:
• Forward consensus EPS for FY1 is $1.99 and FY2 is $2.01.
• Management guidance for full-year adjusted AFFO is narrowed to $3.19 to $3.25 per share, representing a $0.02 increase over the midpoint of February guidance.
• Conviction Stack:
• Thesis Strength: Low (Tactical/Setup-led).
• Evidence Quality: High. The evidence base is robust, with specific transaction data, lease terms, and guidance updates from Q1 2026 earnings and filings.
• Structural Quality: Moderate to High. The balance sheet appears active with significant deployment ($326M YTD) and successful asset recycling. However, the technical structure is currently undefined.
• Rerating Potential: Dependent on the successful execution of the RIDEA platform and the ability to redeploy capital at the expected $0.03 accretion.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen the Case:
• Confirmation of the $0.03 AFFO accretion from RIDEA redeployment in subsequent quarters.
• Continued successful asset recycling at premiums (as seen with the CommuniCare sale).
• Expansion of the RIDEA portfolio beyond the initial U.S. and U.K. markets.
• What Would Invalidate the Case:
• A failure to redeploy capital efficiently, leading to a decline in AFFO per share.
• Significant deterioration in occupancy or reimbursement rates from government programs (Medicare/Medicaid), which drive ~86% of operator revenue.
• Gaps in Evidence:
• Specific RIDEA Metrics: While the platform is active, specific performance metrics (occupancy, NOI) for the RIDEA portfolio are not detailed in the provided evidence, only the expectation of accretion.
• Debt Maturity Schedule: No specific data on debt maturities or refinancing needs for 2026-2027 is provided in the evidence block.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: 1) Strong Q1 2026 capital deployment ($326M YTD) and successful asset recycling (CommuniCare sale at premium). 2) High-quality lease portfolio with 86% of terms expiring post-2030 and 10.4% average yield. 3) Management guidance raised to $3.19-$3.25 AFFO per share. Expected path: Management expects to redeploy capital into RIDEA structures to drive accretion; asset recycling continues to provide liquidity for new investments. Expected horizon: 12-18 months for RIDEA accretion to materialize and for technical structure to form.